Overview
Mermaid diagram (expand to render)
Aurobindo Pharma Ltd. (NSE: AUROPHARMA, BSE: 524804) is an Indian multinational pharmaceutical company headquartered in Hyderabad, Telangana, India["1"]. Founded in 1989, Aurobindo has grown to become one of India's fastest-growing pharmaceutical companies, with a strong focus on generic medications, active pharmaceutical ingredients (APIs), and formulations. The company has a significant portfolio in CNS and neurological disorders, including comprehensive Parkinson's disease treatments, making it a critical player in global access to essential medicines.
India is often called the "pharmacy of the world" due to its massive generic drug manufacturing capacity, supplying approximately 20% of global generic medications by volume["9"]. Aurobindo exemplifies this role, manufacturing and distributing affordable dopaminergic medications that reach patients across 150+ countries. Parkinson's disease affects approximately 5-10 million people globally, with prevalence increasing with age [@global-pd-burden][2]. In India alone, estimates suggest 1-1.5 million people live with Parkinson's disease, making affordable generic medications essential for maintaining quality of life for millions of patients [@india-pd][1].
Company Profile
| Attribute | Details |
|-----------|---------|
| Founded | 1989 |
| Headquarters | Hyderabad, Telangana, India |
| Managing Director | P. V. Ram Prasad Reddy |
| Market Cap | ~₹30,000 Crore (2024) |
| Employees | ~16,000 |
| Manufacturing Facilities | 25+ FDA-approved facilities |
| Global Markets | 150+ countries |
Corporate History
Aurobindo Pharma was established in 1989, initially focusing on pharmaceutical formulations. Over the past three decades, the company has transformed into a vertically integrated pharmaceutical enterprise with capabilities spanning API manufacturing, formulation development, and global distribution. The company's growth trajectory reflects India's emergence as a global pharmaceutical hub.
Key milestones include:
- 1989: Company founded in Hyderabad
- 1995: First API manufacturing facility established
- 2000: US FDA certification for manufacturing facilities
- 2005: International expansion into European markets
- 2010: Biosimilar business unit launched
- 2015: Expansion into specialty pharmaceuticals
- 2020+: Continued growth in complex generics and biosimilars
The company's success is deeply connected to India's strategic position in global pharmaceutical supply chains. India supplies approximately 60% of global generic drug volume and 40% of generic prescriptions in the United States [@india-pharma-industry]. Aurobindo's capabilities span this ecosystem, from API synthesis to finished dosage forms.
Manufacturing Capabilities
Aurobindo operates one of the largest pharmaceutical manufacturing networks in India[1]:
Infrastructure Scale
- 25+ FDA-approved manufacturing facilities: Among the highest in India
- WHO-GMP certified plants: Meeting international quality standards
- API manufacturing hubs: Multiple facilities across India
- Formulation facilities: State-of-the-art oral, topical, and injectable production
Production Capacity
- Formulations: 50+ billion formulation units annually
- APIs: 19,000+ metric tons per year
- Vertical integration: Complete supply chain from API to finished product
- Technology platforms: Oral solids, liquids, semi-solids, injectables, biologics
This massive manufacturing scale enables Aurobindo to supply affordable medications at volume that few companies can match. The company's API capabilities are particularly important for CNS therapeutics, where certain dopaminergic agents require complex synthesis pathways.
Quality Assurance
Aurobindo maintains rigorous quality systems:
- US FDA compliance: Multiple facilities inspected and approved
- EMA certification: European Medicines Agency standards
- WHO prequalification: Essential medicines for global health
- ANVISA, TGA, PMDA: Regulatory approvals across major markets
Global Presence
Aurobindo operates in over 150 countries with strategic market positions[1]:
Geographic Reach
| Region | Market Position |
|--------|-----------------|
| United States | Top 10 generic company, 600+ ANDA approvals |
| Europe | Top 10 in 8+ countries |
| India | Leading generic pharmaceutical company |
| Emerging Markets | Strong presence in Africa, Latin America, Southeast Asia |
US Market Leadership
Aurobindo is among the top 10 generic pharmaceutical companies in the United States by prescriptions. The company's US portfolio includes:
- 830+ ANDA filings: Among the highest in the industry
- 600+ ANDA approvals: Demonstrating regulatory success
- First-to-file opportunities: Paragraph IV certification strategy
- Complex generics: Building in specialty and difficult-to-manufacture products
The US market is particularly important for CNS medications, where Aurobindo supplies generic versions of essential Parkinson's disease therapies at significant cost savings compared to brand-name products.
European Operations
In Europe, Aurobindo maintains presence across major markets:
- United Kingdom: Strong generic market position
- Germany: Major EU market operations
- France: Growing European presence
- Spain, Italy, Netherlands: Strategic market coverage
The company ranks among the top 10 generic companies in eight European countries, based on IQVIA data[1].
Parkinson's Disease Programs
Parkinson's disease is the second most common neurodegenerative disorder worldwide, characterized by progressive loss of dopaminergic neurons in the substantia nigra pars compacta [@global-pd-burden][2]. The resulting dopamine deficiency leads to the cardinal motor symptoms: bradykinesia, resting tremor, rigidity, and postural instability. Non-motor symptoms including sleep disturbance, depression, autonomic dysfunction, and cognitive impairment significantly impact quality of life.
Aurobindo manufactures a comprehensive range of Parkinson's disease medications[1]:
Dopamine Precursors
Levodopa/Carbidopa
Levodopa, combined with carbidopa, remains the gold-standard treatment for Parkinson's disease [@levodopa-therapy][3]. Levodopa is a dopamine precursor that crosses the blood-brain barrier and is decarboxylated to dopamine in the brain. Carbidopa, a peripheral DOPA decarboxylase inhibitor, prevents levodopa degradation in the periphery, increasing brain delivery and reducing peripheral side effects such as nausea and orthostatic hypotension [@levodopa-therapy].
Aurobindo produces:
- Standard immediate-release tablets: 25/100mg, 50/200mg formulations
- Controlled-release variants: For patients requiring more stable plasma levels
- Dispersible formulations: For patients with swallowing difficulties
The generic availability of levodopa/carbidopa from companies like Aurobindo has dramatically reduced treatment costs. While brand-name formulations cost hundreds of dollars monthly, generic alternatives cost as little as $20-30 monthly, enabling broader patient access.
Levodopa/Benserazide
An alternative combination therapy providing similar benefits to levodopa/carbidopa. Benserazide, like carbidopa, inhibits peripheral DOPA decarboxylase, enhancing levodopa brain delivery.
Dopamine Agonists
Dopamine agonists provide dopaminergic stimulation through direct receptor activation, offering several advantages[4]:
- Reduced motor complications: Lower risk of dyskinesias compared to levodopa
- Monotherapy option: Suitable for early disease treatment
- Adjunctive therapy: Used with levodopa in advanced disease
Pramipexole
A non-ergot dopamine agonist selective for D2 and D3 receptors. Pramipexole is available as:
- Immediate-release tablets: 0.125mg, 0.25mg, 0.5mg, 0.75mg, 1mg, 1.5mg
- Extended-release once-daily formulation: Improving compliance
- Generic for Mirapex®: Significant cost savings
Clinical evidence supports pramipexole's efficacy in improving motor symptoms, reducing motor fluctuations, and addressing non-motor symptoms including depression. Studies demonstrate improvements of 20-30% in Unified Parkinson's Disease Rating Scale (UPDRS) motor scores.
Ropinirole
Another non-ergot dopamine agonist with selective D2 receptor activity:
- Immediate-release: Multiple tablet strengths
- Extended-release: Once-daily formulation
- Generic for Requip®: Major cost reduction
Ropinirole's favorable ergot-related risk profile makes it suitable for patients requiring dopamine agonist therapy without ergot-associated complications.
Rotigotine
Transdermal dopamine agonist:
- 24-hour transdermal patch: Continuous dopaminergic stimulation
- Once-daily application: Improved convenience
- Reduced gastrointestinal side effects: Bypasses oral route
MAO-B Inhibitors
Monoamine oxidase B inhibitors prevent dopamine degradation in the brain, extending the half-life of endogenous and exogenous dopamine[5]:
Selegiline
An irreversible MAO-B inhibitor:
- Oral formulations: Multiple tablet strengths
- Adjunctive therapy: Used with levodopa in patients with wearing off
- Potential neuroprotective effects: Beyond symptomatic benefit
Clinical studies suggest selegiline may provide mild symptomatic benefit while potentially slowing disease progression through inhibition of MAO-B-mediated oxidative stress.
Rasagiline
A more selective MAO-B inhibitor:
- Once-daily dosing: Improved compliance
- ADAGIO study: Demonstrated possible disease-modifying effects
- Generic availability: Reducing treatment costs
COMT Inhibitors
Catechol-O-methyltransferase inhibitors block peripheral levodopa metabolism[6]:
Entacapone
A reversible COMT inhibitor:
- Fixed-dose combinations: Levodopa/carbidopa/entacapone in single tablets
- Stand-alone tablets: Adding to existing levodopa therapy
- Generic for Stalevo®: Dramatic cost reduction
Entacapone extends levodopa half-life, reducing end-of-dose wearing off and allowing for more stable plasma levels. Studies demonstrate reduced OFF time and increased ON time without troublesome dyskinesias.
Additional Anti-Parkinsonian Agents
Amantadine
Originally an antiviral, discovered to have anti-parkinsonian properties:
- Symptomatic benefit: Mild dopaminergic effects
- Dyskinesia reduction: Particularly valuable in advanced disease
- Multiple formulations: Immediate and extended-release
Trihexyphenidyl
An anticholinergic agent:
- Early disease: Particularly for tremor-dominant presentation
- Adjunctive therapy: Combined with dopaminergic agents
- Generic availability: Cost-effective option
Bromocriptine
An ergot dopamine agonist:
- Legacy therapy: Well-established efficacy
- Multiple daily dosing: Standard formulation
- Generic availability: Affordable option
Additional CNS Therapeutic Areas
Beyond Parkinson's disease, Aurobindo's CNS portfolio includes[1]:
Epilepsy
Epilepsy affects approximately 50 million people globally, with 10-20 million in India alone[10]. Aurobindo provides comprehensive anti-epileptic medications:
- Carbamazepine: Sodium channel blocker for partial seizures
- Valproic acid: Broad-spectrum anti-epileptic
- Phenytoin: Established partial seizure therapy
- Lamotrigine: Broad-spectrum with favorable cognitive profile
- Levetiracetam: Newer agent with excellent tolerability
- Topiramate: Multiple seizure types including migraine prevention
Alzheimer's Disease
India faces growing Alzheimer's disease burden, with estimates suggesting 1-4 million patients[9]. Aurobindo supplies:
- Donepezil: Acetylcholinesterase inhibitor for mild to moderate disease
- Rivastigmine: Dual cholinesterase inhibitor
- Memantine: NMDA receptor antagonist for moderate to severe disease
- Galantamine: Acetylcholinesterase inhibitor with nicotinic modulation
These medications provide modest but meaningful cognitive and functional benefits. Generic availability from Aurobindo reduces costs dramatically, enabling broader treatment access.
Depression and Psychiatric Disorders
- SSRIs: Sertraline, fluoxetine, escitalopram, paroxetine
- SNRIs: Venlafaxine, duloxetine
- Atypical antidepressants: Bupropion, mirtazapine
- Antipsychotics: Risperidone, olanzapine, quetiapine
- Anxiolytics: Buspirone, alprazolam
Multiple Sclerosis and Neuroimmunology
- Immunomodulators: Disease-modifying therapies
- Symptom management: Spasticity, fatigue, bladder control
Research and Development
Aurobindo's R&D focuses on[1]:
- Oral solids: Tablets, capsules, suspensions
- Novel drug delivery: Extended-release, controlled-release systems
- Complex generics: Bioequivalence challenges, specialized formulations
API Process Development
- Chemical synthesis: Complex API manufacturing
- Process optimization: Scale-up and cost efficiency
- Quality by design: Process analytical technology
Specialty Pharmaceuticals
- Oncology: Generic and specialty cancer therapies
- Immunology: Biosimilar development
- Complex injectables: Sterile manufacturing
Biosimilar Development
Aurobindo has established biosimilar capabilities through[1]:
- Curateq: Biosimilar business unit
- Curateq Bio: Specialized biosimilar company
- Therapeutic areas: Oncology and immunology focus
- Regulatory pathways: FDA, EMA biosimilar pathways
Business Units and subsidiaries
Aurobindo operates through multiple specialized business units[1]:
APUSA (USA Operations)
The US market represents Aurobindo's largest international presence:
- Generic portfolio: 600+ approved products
- First-to-file strategy: Paragraph IV opportunities
- Complex generics: Building specialty portfolio
Europe
- Multi-country presence: Coverage across EU
- Generic leadership: Top 10 position in multiple markets
- Quality excellence: EMA certification
Growth Markets
- Emerging economies: Africa, Latin America, Southeast Asia
- Institutional business: Tenders and government contracts
- Partnership models: Distribution partnerships
Specialty Units
| Unit | Focus |
|------|-------|
| Curateq | Biosimilars |
| Apitoria | API manufacturing |
| Eugia | Specialty products |
Financial Highlights
Aurobindo's financial performance reflects its scale and market position:
- Revenue: ~₹28,000 Crore (FY 2024)
- R&D Investment: ~5% of revenue
- Export Share: ~75% of revenue
- Profitability: Stable margins through operational efficiency
The company's financial model emphasizes:
- Volume growth: Market share expansion
- Product mix: Higher-margin specialty products
- Operational efficiency: Manufacturing scale advantages
- Regulatory milestones: First-to-file and first-to-market opportunities
Competitive Positioning
Global Generic Competition
The global generic pharmaceutical industry is highly competitive, with major players including:
- Teva Pharmaceuticals: Global generic leader
- Mylan (Viatris): Major US generic company
- Sandoz (Novartis): European generic powerhouse
- Dr. Reddy's: Indian competitor with global presence
- Sun Pharmaceutical: Indian generic leader
Aurobindo's Competitive Advantages
- Manufacturing scale: Cost-effective production capacity
- Regulatory track record: US FDA, EMA approvals
- API integration: Vertical supply chain control
- Portfolio breadth: 600+ products across therapeutic areas
- Market access: 150+ country distribution network
Indian Pharmaceutical Industry Context
India's pharmaceutical industry is a global powerhouse[8][9]:
Industry Scale
- Global position: Third-largest by volume, 14th by value
- Generic dominance: 20% of global generic volume
- API manufacturing: Significant global API production
- Export reach: 200+ countries served
Government Initiatives
India's pharmaceutical sector is supported by:
- Production Linked Incentive (PLI) scheme: Manufacturing incentives
- Pharmaceutical Technology Upgradation Assistance Scheme: Quality improvement
- Generic promotion: Government push for generic adoption
- Export incentives: International market development
Challenges and Opportunities
The Indian pharmaceutical industry faces:
- Regulatory harmonization: Alignment with global standards
- API dependency: Some APIs still imported from China
- Price competition: Margin pressure in competitive products
- Quality expectations: Increasing regulatory standards
Opportunities include:
- Biosimilars: Growing biologics market
- Complex generics: Higher-margin specialized products
- Digital health: Integration with telemedicine
- Emerging markets: Africa, Latin America growth
Quality Systems and Regulatory Excellence
Aurobindo maintains comprehensive quality systems:
Regulatory Certifications
- US FDA: Multiple facility approvals, inspection history
- EMA: European marketing authorization
- WHO: Prequalification for essential medicines
- ANVISA: Brazilian regulatory approval
- PMDA: Japanese regulatory approval
- TGA: Australian regulatory approval
Quality Philosophy
- Quality by design: Process analytical technology
- Continuous improvement: Ongoing quality enhancement
- Supply chain integrity: Supplier qualification and monitoring
- Pharmacovigilance: Adverse event monitoring and reporting
Sustainability and Corporate Responsibility
Environmental Practices
- Waste management: Proper pharmaceutical waste disposal
- Water treatment: Effluent treatment facilities
- Energy efficiency: Sustainable manufacturing practices
- Emissions reduction: Carbon footprint initiatives
Social Responsibility
- Healthcare access: Generic medication affordability
- Community health: Health camps and awareness programs
- Education: Supporting science and technology education
- Employment: Creating skilled pharmaceutical jobs
Future Outlook
Several trends will shape Aurobindo's future:
Growth Drivers
Aging populations: Increasing neurological disease prevalence globally
Generic adoption: Healthcare cost pressure driving generic use
Biosimilars: Growing biologics market opportunity
Emerging markets: Africa, Southeast Asia expansion
Complex generics: Specialty product developmentStrategic Priorities
Portfolio expansion: Broader therapeutic coverage
Regulatory excellence: First-to-file strategy
Manufacturing efficiency: Cost leadership
Vertical integration: API to formulation control
Market access: Distribution network expansionClinical Evidence and Treatment Guidelines
Parkinson's Disease Treatment Evidence
The pharmacological management of Parkinson's disease is supported by extensive clinical evidence. The Movement Disorders Society (MDS) evidence-based medicine review provides comprehensive recommendations for PD treatment[3][4][5][6].
Levodopa-Carbidopa Efficacy
Levodopa, combined with carbidopa, remains the gold-standard treatment for Parkinson's disease[3]. Clinical trials demonstrate:
- Motor improvement: 30-50% reduction in UPDRS motor scores in randomized controlled trials
- Quality of life: Significant improvements in PDQ-39 and SF-36 scores
- Long-term outcomes: Sustained efficacy over 5+ years of treatment
Generic formulations from Aurobindo provide bioequivalent efficacy at significantly reduced cost. Studies demonstrate therapeutic equivalence between generic and reference products.
Dopamine Agonist Evidence
Dopamine agonists (pramipexole, ropinirole) provide sustainable dopaminergic stimulation with lower risk of motor complications[4]:
- Early monotherapy: Pramipexole and ropinirole effectively control motor symptoms as initial therapy
- Adjunctive use: When added to levodopa, agonists reduce OFF time and improve ON time
- Non-motor symptoms: Evidence supports benefits for depression, sleep, and fatigue
The CALM-PD study demonstrated pramipexole's efficacy as initial therapy, with improvements sustained at 2-year follow-up.
MAO-B Inhibitor Evidence
Selegiline and rasagiline provide modest symptomatic benefit while potentially offering disease-modifying effects[5]:
- Symptomatic benefit: 2-3 point improvement in UPDRS scores versus placebo
- Wearing off reduction: Reduced end-of-dose phenomenon in patients on levodopa
- Neuroprotection: Preclinical evidence supports reduced oxidative stress
The DATATOP study demonstrated selegiline's symptomatic benefits, while the ADAGIO study suggested possible disease-modifying effects for rasagiline.
COMT Inhibitor Evidence
Entacapone enhances levodopa bioavailability and reduces motor fluctuations[6]:
- Wearing off reduction: 1-2 hours additional ON time daily
- Levodopa dose reduction: Allows 25-30% dose reduction while maintaining efficacy
- Quality of life: Improved UPDRS ADL scores and patient global assessment
Epilepsy Treatment Evidence
Anti-epileptic drugs (AEDs) from Aurobindo are supported by extensive clinical evidence[12]:
- Carbamazepine: First-line for partial seizures, established efficacy in RCTs
- Valproic acid: Broad-spectrum efficacy for generalized and partial seizures
- Levetiracetam: Newer agent with favorable tolerability, broad-spectrum efficacy
- Lamotrigine: Effective with favorable cognitive side effect profile
Alzheimer's Disease Treatment Evidence
Acetylcholinesterase Inhibitors
Donepezil, rivastigmine, and galantamine are approved for mild to moderate Alzheimer's disease[11]:
- Cognitive benefits: 2-4 point improvement in ADAS-Cog scores versus placebo
- Functional benefits: Slower decline in ADL scores
- Global benefits: Improved clinician's impression of change (CIBIC+)
Memantine Evidence
Memantine provides modest benefits in moderate to severe Alzheimer's disease:
- Cognitive stabilization: Reduced decline in cognition and function
- Combination therapy: Added benefit when combined with acetylcholinesterase inhibitors
- Tolerability: Favorable side effect profile compared to placebo
Patient Access and Global Distribution
US Market Access
Aurobindo's US operations provide critical access to affordable medications[1]:
Generic Medication Access
- 600+ approved products: Comprehensive therapeutic coverage
- First-to-file strategy: Paragraph IV certifications for exclusivity
- Competitive pricing: 80-95% below brand-name costs
- Supply reliability: Manufacturing scale ensures consistent supply
Healthcare System Integration
- Medicare/Medicaid: Formulary inclusion in government programs
- Commercial insurance: Payer contracts and preferred positioning
- Chain pharmacy: Major retail pharmacy partnerships
- Healthcare systems: Hospital and health system purchasing
Cost Impact
Generic medications from Aurobindo generate substantial healthcare savings:
- Annual savings: Billions of dollars in generic savings
- Patient access: Reduced out-of-pocket costs
- Payer savings: Reduced prescription costs
- System sustainability: Enables broader formulary coverage
European Market Access
Aurobindo serves European markets through[1]:
Regulatory Pathways
- Centralized procedure: EMA marketing authorization
- Decentralized procedure: National approvals
- Mutual recognition: Cross-border approvals
- Generic applications: Abbreviated applications with bioequivalence data
Distribution Network
- Wholesale partnerships: Major pharmaceutical wholesalers
- Hospital purchasing: Tender-based hospital contracts
- Retail pharmacy: Community pharmacy networks
- Online pharmacies: E-commerce distribution
Emerging Markets
Aurobindo serves 150+ countries across emerging markets[1]:
Africa
- Sub-Saharan presence: Major African market operations
- WHO prequalification: Essential medicines for international procurement
- Government contracts: Ministries of health partnerships
- NGO partnerships: Global health organization collaborations
Latin America
- Brazil operations: Registration and distribution
- Mexico presence: Major Latin American market
- Regional partnerships: Distribution throughout Latin America
- Spanish language: Localized product labeling
Southeast Asia
- India: Domestic market operations
- ASEAN presence: Regional distribution network
- Australia/TGA: Regulatory approval and market access
- Japan/PMDA: Registration in Japanese market
Quality Systems and Regulatory Excellence
Regulatory Certifications
Aurobindo maintains comprehensive regulatory certifications[1]:
US Regulatory
- US FDA inspections: Multiple facilities with approved status
- ANDA approvals: 600+ Abbreviated New Drug Applications
- NDI notifications: New Dietary Ingredient compliance
- cGMP compliance: Current Good Manufacturing Practice
European Regulatory
- EMA marketing authorizations: Centralized procedure approvals
- WHO-GMP: World Health Organization certification
- ISO certifications: Quality management system certifications
Quality Philosophy
- Quality by design: Process analytical technology implementation
- Continuous improvement: Ongoing quality enhancement programs
- Supply chain integrity: Supplier qualification and monitoring
- Pharmacovigilance: Adverse event monitoring systems
Manufacturing Excellence
- Process validation: Comprehensive process validation
- Equipment qualification: IQ, OQ, PQ documentation
- Environmental monitoring: Cleanroom environmental controls
- Laboratory controls: Analytical method validation
Economic Impact
Healthcare Cost Savings
Generic medications from Aurobindo provide substantial savings globally:
United States
- Annual impact: Billions in generic savings
- Medicare/Medicaid: Reduced government expenditure
- Commercial insurance: Lower premium costs
- Patient savings: Reduced out-of-pocket costs
Global Impact
- International markets: Significant savings across 150+ countries
- Healthcare systems: Enabling broader coverage
- Patient access: Improving medication affordability
- System sustainability: Long-term healthcare cost management
Economic Contribution
India Operations
- Employment: 16,000+ direct jobs
- Indirect employment: Additional supply chain positions
- Exports: Major foreign exchange earnings
- Technology development: R&D investment
Global Operations
- Local employment: Staff in international operations
- Regulatory expertise: Specialized workforce development
- Distribution jobs: Logistics and supply chain employment
- Economic development: Supporting healthcare infrastructure
Sustainability and Corporate Responsibility
Environmental Practices
Aurobindo implements sustainable manufacturing practices:
- Waste management: Pharmaceutical waste treatment and disposal
- Water conservation: Effluent treatment and water recycling
- Energy efficiency: Sustainable manufacturing processes
- Emissions reduction: Carbon footprint initiatives
Social Responsibility
- Healthcare access: Affordable medication programs
- Community health: Health awareness programs
- Education: Science and technology education support
- Employment: Creating skilled pharmaceutical jobs
Governance
- Corporate governance: Board oversight and transparency
- Ethics: Code of conduct and business ethics
- Compliance: Regulatory compliance programs
- Risk management: Enterprise risk management systems
See Also
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Dopamine Agonists](/therapeutics/dopamine-agonists)
- [Levodopa](/therapeutics/levodopa)
- [Pharmaceutical Companies](/companies/ad-pipeline-companies)
- [Indian Pharmaceuticals](/companies/indian-pharmaceutical-overview)
- [Generic Pharmaceuticals](/companies/generic-pharmaceuticals-overview)
References
[Aurobindo Pharma Official Website](https://www.aurobindo.com)
[Parkinson's disease in India: epidemiology and burden](https://pubmed.ncbi.nlm.nih.gov/32999228/)
[Global burden of Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/31795498/)
[Levodopa therapy in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/30682274/)
[Dopamine agonists clinical use in Parkinson's disease](https://pubmed.ncbi.nlm.nih.gov/29486711/)
[MAO-B inhibitors in Parkinson's disease management](https://pubmed.ncbi.nlm.nih.gov/28716950/)
[COMT inhibitors in Parkinson's disease treatment](https://pubmed.ncbi.nlm.nih.gov/28492523/)
[Pharmaceutical industry in India](https://pubmed.ncbi.nlm.nih.gov/32559989/)
[Active pharmaceutical ingredient manufacturing in India](https://pubmed.ncbi.nlm.nih.gov/33574289/)
[Generic pharmaceutical industry global impact](https://pubmed.ncbi.nlm.nih.gov/33251849/)
[Alzheimer's disease in India](https://pubmed.ncbi.nlm.nih.gov/33052477/)
[Epilepsy burden in India](https://pubmed.ncbi.nlm.nih.gov/32154987/)Pathway Diagram
The following diagram shows the key molecular relationships involving Aurobindo Pharma Ltd. discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)